René G.C. Santegoeds

Dr. René G.C. Santegoeds

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2018 in Current Radiology Reports
Verified
Journal Article
Open access
PDF file
RSRené G.C. Santegoeds
René G.C. Santegoeds
YTYasin Temel
Yasin Temel
JBJan C. Beckervordersandforth
Jan C. Beckervordersandforth
JOJacobus J. Van Overbeeke
Jacobus J. Van Overbeeke
CHChristianne M. Hoeberigs
Christianne M. Hoeberigs
Purpose of Review Chordoma are rare tumours of the axial skeleton which occur most often at the base of the skull and in the sacrum. Although chordoma are generally slow-growing lesions, the recurrence rate is high and the location makes it often difficult to treat. Both computed tomography (CT) and magnetic resonance imaging (MRI) are crucial in the initial diagnosis, treatment planning and post-treatment follow-up. Recent Findings Basic MRI and CT characteristics of chordoma were described in the late 1980s and early 1990s. Since then, imaging techniques have evolved with increased resolution and new molecular imaging tools are rapidly evolving. New imaging tools have been developed not only to study anatomy, but also physiologic changes and characterization of tissue and assessment of tumour biology. Recent studies show the uptake of multiple PET tracers in chordoma, which may become an important aspect in the diagnosis, follow-up and personalized therapy. Summary This review gives an overview of skull base chordoma histopathology, classic imaging characteristics, radiomics and state-of-the-art imaging techniques that are now emerging in diagnosis, treatment planning and disease monitoring of skull base chordoma.

28 March 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
RSRené G.C. Santegoeds
René G.C. Santegoeds
MAMohammed Alahmari
Mohammed Alahmari
APAlida Annechien Postma
Alida Annechien Postma
NLNorbert J. Liebsch
Norbert J. Liebsch
DWDamien Charles Weber
Damien Charles Weber
Yasin TemelYasin Temel
Yasin Temel
Background: Chordoma are rare tumors of the axial skeleton. The treatment gold standard is surgery, followed by particle radiotherapy. Total resection is usually not achievable in skull base chordoma (SBC) and high recurrence rates are reported. Ectopic recurrence as a first sign of treatment failure is considered rare. Favorable sites of these ectopic recurrences remain unknown. Methods: Five out of 16 SBC patients treated with proton therapy and surgical resection developed ectopic recurrence as a first sign of treatment failure were critically analyzed regarding prior surgery, radiotherapy, and recurrences at follow-up imaging. Results: Eighteen recurrences were defined in five patients. A total of 31 surgeries were performed for primary tumors and recurrences. Seventeen out of eighteen (94%) ectopic recurrences could be related to prior surgical tracts, outside the therapeutic radiation dose. Follow-up imaging showed that tumor recurrence was difficult to distinguish from radiation necrosis and anatomical changes due to surgery. Conclusions: In our cohort, we found uncommon ectopic recurrences in the surgical tract. Our theory is that these recurrences are due to microscopic tumor spill during surgery. These cells did not receive a therapeutic radiation dose. Advances in surgical possibilities and adjusted radiotherapy target volumes might improve local control and survival.

13 November 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
LHLaura M.M. de Haan
Laura M.M. de Haan
MDMerel C.L. Demmink
Merel C.L. Demmink
CZCatharina M.L. Zegers
Catharina M.L. Zegers
RSRené G.C. Santegoeds
René G.C. Santegoeds
MKMark L. Kuijf
Mark L. Kuijf
DEDaniëlle Berty Petra Eekers
Daniëlle Berty Petra Eekers
Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive disability due to bradykinesia, rigidity, and rest tremors. Especially in the treatment of tremors, pharmacological options often fall short. Invasive treatments such as deep brain stimulation are unsuitable in selected patients. Stereotactic radiotherapy (SRT) is a non-invasive alternative. However, implementation is hindered by inconsistent findings across studies. This study aims to evaluate the effect of SRT on tremors in PD patients. A PRISMA-guided systematic review identified 183 records. Six studies (n = 193 patients) met inclusion criteria. Outcomes were assessed after 12 months of SRT treatment. All included studies used single-fraction SRT, prescribed doses ranged from 85-165 Gy, with 130-140 Gy being most frequently used. The ventral intermediate nucleus (VIM) was the most commonly targeted structure in three of the six studies. Across all studies tremor improvement was reported in 71 %-100 % of cases, with severity reduction of 38 %-67 % and tremor elimination in three studies varying from 0 % to 70 % of patients. Three studies noted medication reductions in 6 %-75 % of cases. Quality of life (QoL) and tremor recurrence were inconsistently reported: only one study reported no significant QoL improvement. Recurrence rates ranged from 3 %-24 %. Adverse events were present in 7 (7 %) patients. SRT is a promising non-invasive treatment for medically refractory PD tremor, with substantial tremor reduction and low toxicity. However, limitations such as the inconsistent reporting affect the strength of the findings. Future research should emphasize standardized reporting of treatment parameters and outcomes to strengthen evidence on SRT efficacy.